Although the beneficial effects of HDAC inhibitors have been demonstrated by conducting cell or animal experiments, clinical trials for ccRCC treatment should be conducted to thoroughly understand the therapeutic value of the HDAC inhibitors. This evidence concerns the gene HDAC9 and nonpapillary renal cell carcinoma.